Literature DB >> 26763484

Chronic hepatitis C virus infection, a new cardiovascular risk factor?

Fanny Domont1,2,3, Patrice Cacoub1,3,4,5.   

Abstract

Among the large scope of extrahepatic manifestations related to hepatitis C virus (HCV) infection, many studies recently evaluated the frequency and characteristics of cardiovascular involvement. To assess the current published data on HCV infection and cardiovascular diseases. Published studies on cardiovascular disease, i.e. cerebrovascular accident and ischaemic heart disease in subjects with HCV infection were analysed from literature databases. Subjects with HCV chronic infection have an increased prevalence of carotid atherosclerosis and increased intima-media thickness compared to healthy controls or those with hepatitis B or non-alcoholic steatohepatitis. Active chronic HCV infection appears as an independent risk factor for ischaemic cerebrovascular accidents. Active chronic HCV infection is associated with increased risk of ischaemic heart disease. In some studies, successful interferon-based therapy showed a beneficial impact on the cardiovascular risk. The risk of major cardiovascular events is higher in patients with HCV infection compared to controls, independent of the severity of the liver disease or the common cardiovascular risk factors. The beneficial impact of interferon-based therapy needs to be confirmed with new direct antiviral interferon-free agents in prospective studies with extended follow-up.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  HCV; cardiovascular risk factor; extrahepatic manifestations; ischaemic heart diseases; stroke

Mesh:

Substances:

Year:  2016        PMID: 26763484     DOI: 10.1111/liv.13064

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  11 in total

1.  Impact of DAA-Based Regimens on HCV-Related Extra-Hepatic Damage: A Narrative Review.

Authors:  Evangelista Sagnelli; Caterina Sagnelli; Antonio Russo; Mariantonietta Pisaturo; Clarissa Camaioni; Roberta Astorri; Nicola Coppola
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Metabolic and Cardiovascular Complications in HIV/HCV-Co-infected Patients.

Authors:  Roger Bedimo; Oladapo Abodunde
Journal:  Curr HIV/AIDS Rep       Date:  2016-12       Impact factor: 5.071

Review 3.  Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight.

Authors:  Stefano Ballestri; Fabio Nascimbeni; Dante Romagnoli; Enrica Baldelli; Giovanni Targher; Amedeo Lonardo
Journal:  Int J Mol Sci       Date:  2016-03-09       Impact factor: 5.923

4.  Positive Expression of Human Cytomegalovirus Phosphoprotein 65 in Atherosclerosis.

Authors:  Zhe Wang; Jun Cai; Mingming Zhang; Xiaojing Wang; Hongjie Chi; Haijun Feng; Xinchun Yang
Journal:  Biomed Res Int       Date:  2016-11-20       Impact factor: 3.411

Review 5.  New insights into HCV-related rheumatologic disorders: A review.

Authors:  Patrice Cacoub; Cloé Comarmond
Journal:  J Adv Res       Date:  2016-07-25       Impact factor: 10.479

6.  Comorbidities and medications of patients with chronic hepatitis C under specialist care in the UK.

Authors:  Benjamin Hudson; Alex J Walker; William L Irving
Journal:  J Med Virol       Date:  2017-08-30       Impact factor: 2.327

7.  Use of hypnotics and the risk of or mortality from heart disease: a meta-analysis of observational studies.

Authors:  Young-Hyo Kim; Hong-Bae Kim; Do-Hyoung Kim; Ja-Young Kim; Hyun-Young Shin
Journal:  Korean J Intern Med       Date:  2017-08-28       Impact factor: 2.884

8.  Effect of comedication on ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin therapy in chronic hepatitis C - a real-world study.

Authors:  Krzysztof Adam Simon; Robert Flisiak; Tadeusz Wojciech Łapiński; Ewa Janczewska; Marta Wawrzynowicz-Syczewska; Jerzy Jaroszewicz; Dorota Zarębska-Michaluk; Khalil Nazzal; Beata Bolewska; Jolanta Białkowska; Hanna Berak; Katarzyna Fleischer-Stępniewska; Krzysztof Tomasiewicz; Kornelia Karwowska; Karolina Anna Rostkowska; Anna Piekarska; Olga Tronina; Grzegorz Madej; Aleksander Garlicki; Mariusz Łucejko; Arkadiusz Pisula; Ewa Karpińska; Wiesław Kryczka; Alicja Wiercińska-Drapało; Iwona Mozer-Lisewska; Maciej Stanisław Jabłkowski; Andrzej Horban; Brygida Knysz; Magdalena Tudrujek; Waldemar Halota
Journal:  Clin Exp Hepatol       Date:  2019-09-05

Review 9.  Systemic manifestations of hepatitis C infection.

Authors:  Lydia Tang; Lauren Marcell; Shyam Kottilil
Journal:  Infect Agent Cancer       Date:  2016-05-23       Impact factor: 2.965

10.  Cohort Profile: The Hepatitis C Virus (HCV) Research UK Clinical Database and Biobank.

Authors:  J McLauchlan; H Innes; J F Dillon; G Foster; E Holtham; S McDonald; B Wilkes; S J Hutchinson; W L Irving
Journal:  Int J Epidemiol       Date:  2017-10-01       Impact factor: 9.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.